title: Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.
abstract: We analyzed 27 CML patients treated with imatinib (IM) who developed a BCR-ABLT315I mutation. These patients had poor prognostic features: High or intermediate Sokal index (82%), and lack of CCyR under IM (59%). At T315I discovery, patients were in advanced phase (59%), with clonal evolution (84%). Median time since diagnosis was 39 months, and progression occurred 13 months after IM initiation, regardless of disease phase. Overall survival since IM initiation was 42.5 months for chronic, and 17.5 months for advanced phases, and all patients progressed. This mutation seems related to or (partially?) responsible for progression and poor survival.
authors.affiliation: Hematology Department, Hôpital E. Herriot, Lyon, France. franck-emmanuel.nicolini@chu-lyon.fr
authors.forename: Franck E
authors.initials: FE
authors.lastname: Nicolini
authors.forename: Sandrine
authors.initials: S
authors.lastname: Hayette
authors.forename: Selim
authors.initials: S
authors.lastname: Corm
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Bachy
authors.forename: Dominique
authors.initials: D
authors.lastname: Bories
authors.forename: Michel
authors.initials: M
authors.lastname: Tulliez
authors.forename: François
authors.initials: F
authors.lastname: Guilhot
authors.forename: Laurence
authors.initials: L
authors.lastname: Legros
authors.forename: Frédéric
authors.initials: F
authors.lastname: Maloisel
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Kiladjian
authors.forename: François-Xavier
authors.initials: FX
authors.lastname: Mahon
authors.forename: Quoc-Hung
authors.initials: QH
authors.lastname: Lê
authors.forename: Mauricette
authors.initials: M
authors.lastname: Michallet
authors.forename: Catherine
authors.initials: C
authors.lastname: Roche-Lestienne
authors.forename: Claude
authors.initials: C
authors.lastname: Preudhomme
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D010879:Piperazines / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use*; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl